RxDoctor Payments DataLook up a doctor →

Howard Lippes, MD

Endocrinology, Diabetes & Metabolism · Williamsville, NYNPI 1750343141

Payments from drug & device makers

$139,672in general payments, 2019–2025

Across 1,296 payments — averaging $107.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$81K
  • Boehringer Ingelheim$11K
  • Abbott$9K
  • Dexcom, Inc.$9K
  • Mannkind Corporation$8K
  • Johnson & Johnson$6K
  • plus $17K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk263$81,280
Boehringer Ingelheim95$10,561
Abbott71$8,957
Dexcom, Inc.50$8,750
Mannkind Corporation72$7,524
Johnson & Johnson38$5,826
Lilly USA, LLC187$4,801
AstraZeneca(2 entities)51$1,978
Amgen(2 entities)65$1,793
Sanofi-aventis U.S. LLC59$1,176
AbbVie(2 entities)36$720
Insulet Corporation25$595
Tandem Diabetes Care, Inc.20$590
Amneal Pharmaceuticals LLC21$485
Corcept Therapeutics22$416
Pfizer20$402
Amarin Pharma, Inc.17$302
Radius Health, Inc.17$297
Merck16$275
Ascensia Diabetes Care US Inc.13$249
Ascendis Pharma Endocrinology Inc9$236
Novartis11$208
Recordati_rare_diseases_inc.9$200
Medtronic(2 entities)9$178
Xeris Pharmaceuticals, Inc.8$139
Amphastar Pharmaceuticals, Inc.7$137
Bayer6$122
BETA Bionics, Inc.5$109
Valeritas, Inc.5$96
Chiesi USA, Inc.4$87
Neurocrine Biosciences, Inc.3$80
IBSA Pharma Inc.4$74
Sequel Med Tech, LLC3$71
Almatica Pharma LLC3$65
Ipsen Biopharmaceuticals, Inc4$64
Amryt Pharma Holdings Ltd3$64
Kyowa Kirin, Inc.2$55
Zealand Pharma US, Inc.3$53
Gilead2$51
Senseonics, Incorporated3$47
Daiichi Sankyo Inc.2$46
Clarus Therapeutics Inc.3$46
Exact Sciences2$43
GSK3$42
Nestle Healthcare Nutrition Inc.2$35
Lifescan, Inc.2$34
Ultragenyx Pharmaceutical Inc.2$33
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$32
Optinose US, Inc.2$29
Esperion Therapeutics, Inc.2$28
Biohaven Pharmaceuticals, Inc.2$26
Takeda Pharmaceuticals U.S.A., Inc.2$25
Rhythm Pharmaceuticals, Inc.1$24
Mirum Pharmaceuticals, Inc.1$23
EUSA Pharma (US) LLC1$22
Eisai Inc.1$18
Zyla Life Sciences, Inc.1$16
ARS Pharmaceuticals Operations, Inc.1$14
Antares Pharma, Inc.1$13
Cequr Corporation2$12

How this compares

$139,672 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York →

Medicare billing

Part B allowed, 2024
$28,048
Medicare patients
132
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Williamsville

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →